Traditional and new composite endpoints in heart failure clinical trials

Facilitating comprehensive efficacy assessments and improving trial efficiency

Stefan D. Anker, Stefan Schroeder, Dan Atar, Jeroen J. Bax, Claudio Ceconi, Martin R. Cowie, Adam Crisp, Fabienne Dominjon, Ian Ford, Hossein Ardeschir Ghofrani, Savion Gropper, Gerhard Hindricks, Mark A. Hlatky, Richard Holcomb, Narimon Honarpour, J. Wouter Jukema, Albert M. Kim, Michael Kunz, Martin Lefkowitz, Chantal Le Floch & 12 others Ulf Landmesser, Theresa A. McDonagh, John J. McMurray, B. Merkely, Milton Packer, Krishna Prasad, James Revkin, Giuseppe M C Rosano, Ransi Somaratne, Wendy Gattis Stough, Adriaan A. Voors, Frank Ruschitzka

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical trials still must enrol large numbers of patients to accrue a sufficient number of outcome events and have adequate power to draw conclusions about the efficacy and safety of new treatments for heart failure. Additionally, the societal and health system perspectives on heart failure have raised interest in ascertaining the effects of therapy on outcomes such as repeat hospitalization and the patient's burden of disease. Thus, novel methods for using composite endpoints in clinical trials (e.g. clinical status composite endpoints, recurrent event analyses) are being applied in current and planned trials. Endpoints that measure functional status or reflect the patient experience are important but used cautiously because heart failure treatments may improve function yet have adverse effects on mortality. This paper discusses the use of traditional and new composite endpoints, identifies qualities of robust composites, and outlines opportunities for future research.

Original languageEnglish
Pages (from-to)482-489
Number of pages8
JournalEuropean Journal of Heart Failure
Volume18
Issue number5
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Heart Failure
Clinical Trials
Treatment Failure
Hospitalization
Therapeutics
Safety
Mortality
Health

Keywords

  • Clinical trial
  • Endpoint determination
  • Heart failure
  • Surrogate endpoints

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Traditional and new composite endpoints in heart failure clinical trials : Facilitating comprehensive efficacy assessments and improving trial efficiency. / Anker, Stefan D.; Schroeder, Stefan; Atar, Dan; Bax, Jeroen J.; Ceconi, Claudio; Cowie, Martin R.; Crisp, Adam; Dominjon, Fabienne; Ford, Ian; Ghofrani, Hossein Ardeschir; Gropper, Savion; Hindricks, Gerhard; Hlatky, Mark A.; Holcomb, Richard; Honarpour, Narimon; Jukema, J. Wouter; Kim, Albert M.; Kunz, Michael; Lefkowitz, Martin; Le Floch, Chantal; Landmesser, Ulf; McDonagh, Theresa A.; McMurray, John J.; Merkely, B.; Packer, Milton; Prasad, Krishna; Revkin, James; Rosano, Giuseppe M C; Somaratne, Ransi; Stough, Wendy Gattis; Voors, Adriaan A.; Ruschitzka, Frank.

In: European Journal of Heart Failure, Vol. 18, No. 5, 01.05.2016, p. 482-489.

Research output: Contribution to journalArticle

Anker, SD, Schroeder, S, Atar, D, Bax, JJ, Ceconi, C, Cowie, MR, Crisp, A, Dominjon, F, Ford, I, Ghofrani, HA, Gropper, S, Hindricks, G, Hlatky, MA, Holcomb, R, Honarpour, N, Jukema, JW, Kim, AM, Kunz, M, Lefkowitz, M, Le Floch, C, Landmesser, U, McDonagh, TA, McMurray, JJ, Merkely, B, Packer, M, Prasad, K, Revkin, J, Rosano, GMC, Somaratne, R, Stough, WG, Voors, AA & Ruschitzka, F 2016, 'Traditional and new composite endpoints in heart failure clinical trials: Facilitating comprehensive efficacy assessments and improving trial efficiency', European Journal of Heart Failure, vol. 18, no. 5, pp. 482-489. https://doi.org/10.1002/ejhf.516
Anker, Stefan D. ; Schroeder, Stefan ; Atar, Dan ; Bax, Jeroen J. ; Ceconi, Claudio ; Cowie, Martin R. ; Crisp, Adam ; Dominjon, Fabienne ; Ford, Ian ; Ghofrani, Hossein Ardeschir ; Gropper, Savion ; Hindricks, Gerhard ; Hlatky, Mark A. ; Holcomb, Richard ; Honarpour, Narimon ; Jukema, J. Wouter ; Kim, Albert M. ; Kunz, Michael ; Lefkowitz, Martin ; Le Floch, Chantal ; Landmesser, Ulf ; McDonagh, Theresa A. ; McMurray, John J. ; Merkely, B. ; Packer, Milton ; Prasad, Krishna ; Revkin, James ; Rosano, Giuseppe M C ; Somaratne, Ransi ; Stough, Wendy Gattis ; Voors, Adriaan A. ; Ruschitzka, Frank. / Traditional and new composite endpoints in heart failure clinical trials : Facilitating comprehensive efficacy assessments and improving trial efficiency. In: European Journal of Heart Failure. 2016 ; Vol. 18, No. 5. pp. 482-489.
@article{28e13122f06d4413bdbba7e758da837e,
title = "Traditional and new composite endpoints in heart failure clinical trials: Facilitating comprehensive efficacy assessments and improving trial efficiency",
abstract = "Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical trials still must enrol large numbers of patients to accrue a sufficient number of outcome events and have adequate power to draw conclusions about the efficacy and safety of new treatments for heart failure. Additionally, the societal and health system perspectives on heart failure have raised interest in ascertaining the effects of therapy on outcomes such as repeat hospitalization and the patient's burden of disease. Thus, novel methods for using composite endpoints in clinical trials (e.g. clinical status composite endpoints, recurrent event analyses) are being applied in current and planned trials. Endpoints that measure functional status or reflect the patient experience are important but used cautiously because heart failure treatments may improve function yet have adverse effects on mortality. This paper discusses the use of traditional and new composite endpoints, identifies qualities of robust composites, and outlines opportunities for future research.",
keywords = "Clinical trial, Endpoint determination, Heart failure, Surrogate endpoints",
author = "Anker, {Stefan D.} and Stefan Schroeder and Dan Atar and Bax, {Jeroen J.} and Claudio Ceconi and Cowie, {Martin R.} and Adam Crisp and Fabienne Dominjon and Ian Ford and Ghofrani, {Hossein Ardeschir} and Savion Gropper and Gerhard Hindricks and Hlatky, {Mark A.} and Richard Holcomb and Narimon Honarpour and Jukema, {J. Wouter} and Kim, {Albert M.} and Michael Kunz and Martin Lefkowitz and {Le Floch}, Chantal and Ulf Landmesser and McDonagh, {Theresa A.} and McMurray, {John J.} and B. Merkely and Milton Packer and Krishna Prasad and James Revkin and Rosano, {Giuseppe M C} and Ransi Somaratne and Stough, {Wendy Gattis} and Voors, {Adriaan A.} and Frank Ruschitzka",
year = "2016",
month = "5",
day = "1",
doi = "10.1002/ejhf.516",
language = "English",
volume = "18",
pages = "482--489",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Traditional and new composite endpoints in heart failure clinical trials

T2 - Facilitating comprehensive efficacy assessments and improving trial efficiency

AU - Anker, Stefan D.

AU - Schroeder, Stefan

AU - Atar, Dan

AU - Bax, Jeroen J.

AU - Ceconi, Claudio

AU - Cowie, Martin R.

AU - Crisp, Adam

AU - Dominjon, Fabienne

AU - Ford, Ian

AU - Ghofrani, Hossein Ardeschir

AU - Gropper, Savion

AU - Hindricks, Gerhard

AU - Hlatky, Mark A.

AU - Holcomb, Richard

AU - Honarpour, Narimon

AU - Jukema, J. Wouter

AU - Kim, Albert M.

AU - Kunz, Michael

AU - Lefkowitz, Martin

AU - Le Floch, Chantal

AU - Landmesser, Ulf

AU - McDonagh, Theresa A.

AU - McMurray, John J.

AU - Merkely, B.

AU - Packer, Milton

AU - Prasad, Krishna

AU - Revkin, James

AU - Rosano, Giuseppe M C

AU - Somaratne, Ransi

AU - Stough, Wendy Gattis

AU - Voors, Adriaan A.

AU - Ruschitzka, Frank

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical trials still must enrol large numbers of patients to accrue a sufficient number of outcome events and have adequate power to draw conclusions about the efficacy and safety of new treatments for heart failure. Additionally, the societal and health system perspectives on heart failure have raised interest in ascertaining the effects of therapy on outcomes such as repeat hospitalization and the patient's burden of disease. Thus, novel methods for using composite endpoints in clinical trials (e.g. clinical status composite endpoints, recurrent event analyses) are being applied in current and planned trials. Endpoints that measure functional status or reflect the patient experience are important but used cautiously because heart failure treatments may improve function yet have adverse effects on mortality. This paper discusses the use of traditional and new composite endpoints, identifies qualities of robust composites, and outlines opportunities for future research.

AB - Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical trials still must enrol large numbers of patients to accrue a sufficient number of outcome events and have adequate power to draw conclusions about the efficacy and safety of new treatments for heart failure. Additionally, the societal and health system perspectives on heart failure have raised interest in ascertaining the effects of therapy on outcomes such as repeat hospitalization and the patient's burden of disease. Thus, novel methods for using composite endpoints in clinical trials (e.g. clinical status composite endpoints, recurrent event analyses) are being applied in current and planned trials. Endpoints that measure functional status or reflect the patient experience are important but used cautiously because heart failure treatments may improve function yet have adverse effects on mortality. This paper discusses the use of traditional and new composite endpoints, identifies qualities of robust composites, and outlines opportunities for future research.

KW - Clinical trial

KW - Endpoint determination

KW - Heart failure

KW - Surrogate endpoints

UR - http://www.scopus.com/inward/record.url?scp=84963679505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963679505&partnerID=8YFLogxK

U2 - 10.1002/ejhf.516

DO - 10.1002/ejhf.516

M3 - Article

VL - 18

SP - 482

EP - 489

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 5

ER -